Taken together, this study supports the potential of CyPA as a novel biomarker for STEMI risk assessment and provides new ideas and evidence for precise stratification and early warning of cardiovascular disease.These findings are consistent with previous research, which also highlighted the important role of CyPA in cardiovascular diseases, particularly in the context of acute coronary syndrome and myocardial infarction (13–15). This evidence concerns the gene PPIA and myocardial infarction.